A Review of Research Conducted with Probiotic<i> E. coli</i> Marketed as Symbioflor

Beimfohr, Claudia

doi:10.1155/2016/3535621

Cited by 17 publications

(11 citation statements)

References 36 publications

(73 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Escherichia coli Nissle 1917 (EcN) has been used as a probiotic since its isolation over 100 years ago 21 . In its unengineered form, EcN has been used to treat various gastrointestinal conditions, including inflammatory bowel disease and irritable bowel syndrome 18,19 .…”

Section: Design Of Engineered Therapeutic Strains For the Human Gutmentioning

confidence: 99%

Developing a new class of engineered live bacterial therapeutics to treat human diseases

et al. 2020

View full text Add to dashboard Cite

A complex interplay of metabolic and immunological mechanisms underlies many diseases that represent a substantial unmet medical need. There is an increasing appreciation of the role microbes play in human health and disease, and evidence is accumulating that a new class of live biotherapeutics comprised of engineered microbes could address specific mechanisms of disease. Using the tools of synthetic biology, nonpathogenic bacteria can be designed to sense and respond to environmental signals in order to consume harmful compounds and deliver therapeutic effectors. In this perspective, we describe considerations for the design and development of engineered live biotherapeutics to achieve regulatory and patient acceptance. Regulatory considerations for live biotherapeutic products Live biotherapeutic products (LBPs) are defined as live organisms designed and developed to treat, cure, or prevent a disease or condition in humans 10. Notably, LBPs exclude vaccines, filterable viruses, oncolytic viruses, and organisms used as vectors for transferring genes into the host. LBPs are distinguished from probiotic supplements on the basis of their labeling claims, as

show abstract

Section: Design Of Engineered Therapeutic Strains For the Human Gutmentioning

confidence: 99%

Developing a new class of engineered live bacterial therapeutics to treat human diseases

et al. 2020

View full text Add to dashboard Cite

show abstract

“…bulgaricus and L. delbrueckii subsp. lactis 158 AS-48 E. faecalis AS-48Gram-positive and Gram-negative 159 IId peptidesUnmodified, linear, non-pediocin-like, single-peptide bacteriocinsMicrocin S E. coli G3/10 E. coli G3/10 136 Rhamnosin A Lactobacillus rhamnosus strain 68 Micrococcus lysodeikticus ATCC 4698 138 Bac32Vancomycin-resistant E. faecium (VRE) 200 E. faecium, E. hirae , and E. durans 139 Examples of Class II (IIe) have not yet been described from human gut isolates. Classification of bacteriocins is based on Cotter et al, 2013.…”

Section: Peptidic Antimicrobial Activity In the Gutmentioning

confidence: 99%

“…There were a few representatives of this class identified from human gut in databases. Microcin S is a bacteriocin produced by E. coli G3/10 that is part of the probiotic marketed as Symbioflor, constituted by six different E. coli genotypes, and used for gastrointestinal disorder treatments, especially intestinal bowel syndrome (IBS) 136 . Microcin S inhibits the adhesion of the enteropathogenic E. coli E238/6 to intestinal epithelial cells 137 .…”

Section: Peptidic Antimicrobial Activity In the Gutmentioning

confidence: 99%

Gut microbiota as a source of novel antimicrobials

et al. 2018

View full text Add to dashboard Cite

Bacteria, Archaea, Eukarya and viruses coexist in the human gut, and this coexistence is functionally balanced by symbiotic or antagonistic relationships. Antagonism is often characterized by the production of antimicrobials against other organisms occupying the same environmental niche. Indeed, close co-evolution in the gut has led to the development of specialized antimicrobials, which is attracting increased attention as these may serve as novel alternatives to antibiotics and thereby help to address the global problem of antimicrobial resistance. The gastrointestinal (GI) tract is especially suitable for finding novel antimicrobials due to the vast array of microbes that inhabit it, and a considerable number of antimicrobial producers of both wide and narrow spectrum have been described. In this review, we summarize some of the antimicrobial compounds that are produced by bacteria isolated from the gut environment, with a special focus on bacteriocins. We also evaluate the potential therapeutic application of these compounds to maintain homeostasis in the gut and the biocontrol of pathogenic bacteria.

show abstract

“…Although the most frequently used probiotics are lactic bacteria, mainly the Lactobacillus and Bifidobacterium genera, some Escherichia coli strains were also shown to have beneficial effects on human health. These strains constitute the basis of at least three commercially available probiotic products, known under the commercial names Mutaflor ® , Symbioflor2 ® , and Colinfant ® [2,3]. E. coli Nissle 1917 (Nissle), the active component of Mutaflor ® , is one of the most documented probiotics for therapeutic applications.…”

Section: Introductionmentioning

confidence: 99%

Symbioflor2® Escherichia coli Genotypes Enhance Ileal and Colonic Gene Expression Associated with Mucosal Defense in Gnotobiotic Mice

et al. 2020

Self Cite

View full text Add to dashboard Cite

Symbioflor2® is a probiotic product composed of six Escherichia coli genotypes, which has a beneficial effect on irritable bowel syndrome. Our objective was to understand the individual impact of each of the six genotypes on the host, together with the combined impact of the six in the compound Symbioflor2®. Gnotobiotic mice were mono-associated with one of the six genotypes or associated with the compound product. Ileal and colonic gene expression profiling was carried out, and data were compared between the different groups of gnotobiotic mice, along with that obtained from conventional (CV) mice and mice colonized with the probiotic E. coli Nissle 1917. We show that Symbioflor2® genotypes induce intestinal transcriptional responses involved in defense and immune mechanisms. Using mice associated with Symbioflor2®, we reveal that the product elicits a balanced response from the host without any predominance of a single genotype. The Nissle strain and the six bacterial genotypes have different effects on the intestinal gene expression, suggesting that the impacts of these probiotics are not redundant. Our data show the effect of the Symbioflor2® genotypes at the molecular level in the digestive tract, which further highlights their beneficial action on several aspects of intestinal physiology.

show abstract

A Review of Research Conducted with Probiotic E. coli Marketed as Symbioflor

Cited by 17 publications

References 36 publications

Developing a new class of engineered live bacterial therapeutics to treat human diseases

Developing a new class of engineered live bacterial therapeutics to treat human diseases

Gut microbiota as a source of novel antimicrobials

Symbioflor2® Escherichia coli Genotypes Enhance Ileal and Colonic Gene Expression Associated with Mucosal Defense in Gnotobiotic Mice

Contact Info

Product

Resources

About